drugset / Trial / NCT01039389

Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease

NCT01039389 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study in patients with chronic stable coronary artery disease treatable by percutaneous coronary intervention (PCI) is to evaluate the long-term efficacy and safety of the orally taken selective I(f)-inhibitor Ivabradine (Procoralan®, Servier Switzerland) with regard to the promotion of collateral growth.

Timeline

Start
2009-10
Primary completion
2013-03
Completion
2013-03

Outcome

Met primary endpoint

paper The difference in CFI between the 6-month follow-up and baseline examination amounted to -0.031±0.090 in the placebo group and to +0.040±0.094 in the ivabradine group (p=0.0113). PMID 24186565 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivabradine Small molecule 5 mg Oral